Education
About Us
Working with TipRanks
Follow Us
Organogenesis Holdings (ORGO)
:ORGO
ORGO Stock Chart & Stats
$4.08
-$0.06(-1.89%)
At close: 4:00 PM EST
$4.08
-$0.06(-1.89%)
Day’s Range― - ―
52-Week Range$2.61 - $7.08
Previous CloseN/A
Volume97.61K
Average Volume (3M)2.66M
Market Cap
$668.83M
Enterprise Value$659.47M
Total Cash (Recent Filing)$64.37M
Total Debt (Recent Filing)$40.81M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Feb 26, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding126,912,140
10 Day Avg. Volume1,876,606
30 Day Avg. Volume2,658,641
Financial Highlights & Ratios
PEG Ratio-5.91
Price to Book (P/B)1.09
Price to Sales (P/S)0.87
P/FCF Ratio100.90
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.42
Enterprise Value/Gross Profit1.90
Enterprise Value/Ebitda33.39
Forecast
1Y Price Target
$9.00Price Target Upside120.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.15
Revenue Forecast (FY)$511.05M
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessImprovements in function were statistically significant across both trials.
Market ConfidenceAnalyst's recommendation for ORGO is a Buy, with the belief that as ORGO produces solid results, valuation will improve, allowing shares to move higher.
Regulatory ProgressThe company announced the successful completion of its Type-B meeting with the FDA, allowing it to move ahead with its BLA submission for ReNu.
Bears Say
Clinical Trial SetbackThe second Phase 3 trial did not achieve statistical significance for its primary endpoint, as the control group had better-than-expected improvements in pain.
Pricing AmbiguityThere is still some ambiguity around pricing for these products given the language used in the update, but it does not change the pricing structure CMS put in place.
Organogenesis Holdings News
ORGO FAQ
What was Organogenesis Holdings’s price range in the past 12 months?
Organogenesis Holdings lowest stock price was $2.61 and its highest was $7.08 in the past 12 months.
What is Organogenesis Holdings’s market cap?
Organogenesis Holdings’s market cap is $668.83M.
When is Organogenesis Holdings’s upcoming earnings report date?
Organogenesis Holdings’s upcoming earnings report date is Feb 26, 2026 which is in 68 days.
How were Organogenesis Holdings’s earnings last quarter?
Organogenesis Holdings released its earnings results on Nov 06, 2025. The company reported $0.123 earnings per share for the quarter, beating the consensus estimate of $0.065 by $0.058.
Is Organogenesis Holdings overvalued?
According to Wall Street analysts Organogenesis Holdings’s price is currently Undervalued.
Does Organogenesis Holdings pay dividends?
Organogenesis Holdings does not currently pay dividends.
What is Organogenesis Holdings’s EPS estimate?
Organogenesis Holdings’s EPS estimate is 0.22.
How many shares outstanding does Organogenesis Holdings have?
Organogenesis Holdings has 126,912,140 shares outstanding.
What happened to Organogenesis Holdings’s price movement after its last earnings report?
Organogenesis Holdings reported an EPS of $0.123 in its last earnings report, beating expectations of $0.065. Following the earnings report the stock price went up 44.73%.
Which hedge fund is a major shareholder of Organogenesis Holdings?
Currently, no hedge funds are holding shares in ORGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organogenesis Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (120.59% Upside)
$9.00 (120.59% Upside)
Blogger Sentiment
Bullish
ORGO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.61%
12-Months-Change
Fundamentals
Return on Equity
0.30%
Trailing 12-Months
Asset Growth
14.24%
Trailing 12-Months
Company Description
Organogenesis Holdings
Organogenesis Holdings (ORGO) is a leading regenerative medicine company that specializes in developing and commercializing innovative products for the treatment of wounds and surgical procedures. The company operates primarily in the biotechnology and healthcare sectors, focusing on advanced wound care and surgical biologics. Its core products include dermal regeneration matrices, cellular therapies, and other regenerative medicine solutions designed to enhance healing and improve patient outcomes.
ORGO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong performance in terms of revenue growth, exceeding guidance, and positive developments with CMS policy changes. However, there were notable challenges with the ReNu Phase III trial results, delays in LCD coverage submission, a slight decrease in gross profit margin, and a significant decrease in cash position.View all ORGO earnings summariesORGO Stock 12 Month Forecast
Average Price Target
$9.00
▲(120.59% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---